A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study. Protocol GS-US-203-0109

ID Number 09-2183

Principal Investigator(s)
Thomas D Schiano

Department(s) or Division(s)
Liver Diseases

Description

Gilead is offering an extension protocol providing Truvada (tenofovir) to all interested subjects who complete 96 weeks of the GS-US-203-0107 study (GCO 07-0571). The duration of this protocol will be 5 years.



Contact Information
Yasir Qureshi
(212) 659-8041
yasir.qureshi@mountsinai.org


Recruiting Patients: Yes